AgroSpectrum ASIA
Envisaging Future | Updating Present

Bayer secures US court approval for $7.25 billion Roundup settlement

24 November 2026 | News

The nationwide class settlement establishes a long-term compensation programme for current and future non-Hodgkin's lymphoma claims linked to alleged Roundup exposure.



A Missouri state court granted final approval on 20 November 2026 to Bayer's $7.25 billion nationwide Roundup class settlement, marking a significant development in the German agrochemical company's efforts to contain its US litigation costs. The agreement establishes a compensation programme for eligible claimants alleging that exposure to the glyphosate-based herbicide caused non-Hodgkin's lymphoma.

Under the settlement, Bayer subsidiary Monsanto will make capped annual payments over a period of up to 21 years. The programme covers eligible individuals alleging exposure to Roundup before 17 February 2026 who have been diagnosed with non-Hodgkin's lymphoma or receive a diagnosis within 16 years of the agreement taking effect.

The court approval follows a favourable US Supreme Court ruling for Monsanto in the Durnell case in June 2026, concerning failure-to-warn claims. Bayer said the two legal developments form part of its strategy to reduce litigation risks and improve certainty over future liabilities. The settlement contains no admission of liability or wrongdoing and remains subject to appeal, which would suspend further payments until the appeals process concludes.